Acquired Company

AbbVie acquired Apogee Therapeutics on 9/3/2026 for $135.11 per share in cash, representing a total equity value of approximately US $10.9 billion.

Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc. Show more

One Letterman Drive, San Francisco, CA, 94129-1492, United States

https://www.apogeetherapeutics.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

10.22B

52 Wk Range

$35.39 - $135.09

Previous Close

$135.07

Open

$135.07

Volume

N/A

Day Range

$135.07 - $135.07

Enterprise Value

9.258B

Cash

971.9M

Avg Qtr Burn

-71.38M

Insider Ownership

2.32%

Institutional Own.

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
APG777 Details Atopic dermatitis	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APG777 Details Moderate-to-severe asthma	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zumilokibart (APG777) (IL-13 Antibody) Details Eosinophilic Esophagitis	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APG279 (APG777 + APG990) Details Atopic Dermatitis (AD)	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APG808 Details Allergic diseases Type 2, Chronic obstructive pulmonary disease, Asthma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APG990 Details Atopic dermatitis	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APG333 Details Asthma, Chronic obstructive pulmonary disease	Phase 1 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APG273 (IL-13/TSLP Antibody) Details Asthma, Chronic Obstructive Pulmonary Disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.